EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and safety of subcutaneous venom immunotherapy in children: A 24‐year experience in a pediatric tertiary care center

Mattia Giovannini iD, Francesco Catamerò iD, Marzio Masini, Federico Gelain, Elio Novembre, Simona Barni iD, Giulia Liccioli iD, Lucrezia Sarti iD, Leonardo Tomei iD, Benedetta Pessina iD, Claudia Valleriani iD, Chiara Marzi iD und 3 weitere

Pediatric Allergy and Immunology · 2025-09 · 36 (9)

DOI: 10.1111/pai.70195 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Allergy and Immunology, online erschienen am 01.09.2025. Verfasst von Mattia Giovannini und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, University of Florence, Florence, Italy. Hauptthemen laut MEDLINE: Desensitization, Immunologic, Insect Bites and Stings, Allergens, Bee Venoms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hymenoptera venom allergy is a significant cause of morbidity and mortality, also in pediatric patients, highlighting the importance of effective management through venom immunotherapy (VIT). This study aimed to evaluate the safety profile of VIT, identify factors associated with adverse reactions (ARs), assess the accuracy of insect identification and its impact on VIT extract selection, and determine treatment efficacy by analyzing ARs following re‐sting.

Methods

The medical charts of patients followed up at the Allergy Unit of Meyer Children's Hospital IRCCS, Florence, Italy, who completed a VIT cycle between 1997 and 2021 were retrospectively analyzed. VIT extract selection was guided by a diagnostic workup following the European Academy of Allergy and Clinical Immunology guidelines and the Italian Consensus on Hymenoptera venom allergy management. We implemented a cluster protocol and adjusted it as needed for ARs during VIT.

Results

Fifty‐eight patients, from a total of 60 VIT (2 patients underwent VIT for both Vespula and Polistes) were included, using the following extracts: 17 Apis mellifera (28.4%), 20 Vespula (33.3%), 20 Polistes (33.3%), and 3 Vespa crabro (5.0%). Upon the 3739 injections administered, 355 ARs (9.5%) occurred: local reactions (LRs), 306 (8.2%); extended local reactions (ELRs), 34 (0.9%); and systemic reactions (SRs), 15 (0.4%). The build‐up phase was associated with a higher number of ARs and LRs compared with the maintenance phase during VIT ( p < .0001), normalized by the number of injections. No other significant factors related to the risk of developing any ARs were highlighted. The highest SR rate was found in the VIT for Polistes , with no significant differences in AR proportions among the venom extracts. Thirty patients reported 51 re‐stings following VIT, with only 2 of 51 (3.9%) resulting in SRs. These reactions occurred in individuals stung by a different Hymenoptera species from the one targeted during the VIT.

Conclusion

Cluster protocol VIT is safe and effective in pediatric patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Desensitization, ImmunologicInsect Bites and StingsAllergensBee VenomsWasp VenomsHymenopteraHypersensitivityArthropod VenomsHumansMaleFemaleChildRetrospective StudiesTertiary Care CentersChild, PreschoolAnimalsAdolescentTreatment OutcomeInfantItalyInjections, Subcutaneous

Stichwörter der Autor:innen

adverse reactionanaphylaxischildrenhymenopteravenom immunotherapy

Substanzen

AllergensBee VenomsWasp VenomsArthropod Venoms

Autor:innen und Institutionen

  • Department of Health Sciences, University of Florence, Florence, Italy.
  • Allergy Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
  • Immunology Laboratory, Meyer Children's Hospital IRCCS, Florence, Italy.
  • Department of Statistics, Computer Science and Applications, "G. Parenti," University of Florence, Florence, Italy.
  • NIHR Imperial Biomedical Research Centre, London, UK.
  • National Heart and Lung Institute, Imperial College, London, UK.

ORCID-Profile: Mattia Giovannini, Francesco Catamerò, Simona Barni, Giulia Liccioli, Lucrezia Sarti, Leonardo Tomei, Benedetta Pessina, Claudia Valleriani, Chiara Marzi, Michela Baccini, Mohamed Shamji, Francesca Mori

Zitieren

APA

Giovannini, M., Catamerò, F., Masini, M., Gelain, F., Novembre, E., Barni, S., Liccioli, G., Sarti, L., Tomei, L., Pessina, B., Valleriani, C., Marzi, C., Baccini, M., Shamji, M., & Mori, F. (2025). Efficacy and safety of subcutaneous venom immunotherapy in children: A 24‐year experience in a pediatric tertiary care center. Pediatric Allergy and Immunology, 36(9). https://doi.org/10.1111/pai.70195

Vancouver

Giovannini M, Catamerò F, Masini M, Gelain F, Novembre E, Barni S, et al. Efficacy and safety of subcutaneous venom immunotherapy in children: A 24‐year experience in a pediatric tertiary care center. Pediatric Allergy and Immunology. 2025;36(9). doi:10.1111/pai.70195

BibTeX
@article{Giovannini2025,
  author = {Giovannini, Mattia and Catamerò, Francesco and Masini, Marzio and Gelain, Federico and Novembre, Elio and Barni, Simona and Liccioli, Giulia and Sarti, Lucrezia and Tomei, Leonardo and Pessina, Benedetta and Valleriani, Claudia and Marzi, Chiara and Baccini, Michela and Shamji, Mohamed and Mori, Francesca},
  title = {Efficacy and safety of subcutaneous venom immunotherapy in children: A 24‐year experience in a pediatric tertiary care center},
  journal = {Pediatric Allergy and Immunology},
  year = {2025},
  volume = {36},
  number = {9},
  doi = {10.1111/pai.70195}
}
Kostenlos starten →